NCT06521762 - Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Immune Checkpoint Inhibitor-Related Diarrhea and Colitis

Interventions

DRUG

Etrasimod

2 mg/day oral tablet

DRUG

Placebo

matching placebo oral tablet

DRUG

Corticosteroids

Corticosteroids will be given in conjunction with study drug or placebo

Trial Locations (1)

RECRUITING

Yale Cancer Center, New Haven